Acomhal Research is a biotech company focused on oncology therapeutics. The company develops targeted adjunct cancer therapies aimed at chemo-resistant cells to disrupt tumor recurrence and improve outcomes across glioblastoma, breast, colon, lung, and pancreatic cancers. Based in Roanoke, Virginia, they collaborate with scientists and clinicians to advance oncology science and translate research into patient care. Their work emphasizes advancing cancer treatment by targeting resistant cancer stem cells and relapse mechanisms.
No recent deals for this company.